Oculus +27% as oral, throat infection products gain approval in Mexico

Oculus Innovative Sciences (OCLS +27%) says Mexican regulators approved its Microcyn60 Oral Care family of products intended for use as an adjunct treatment in mouth and throat infections.

OCLS says the commercialization of its Microcyn technology for the new indication lays the foundation for its introduction into other international markets, particularly Europe.

The first oral care product to be launched by OCLS' Latin American partner, More Pharma, will be Microdacyn60 Bucofaringeo.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs